A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

August 9, 2024

Study Completion Date

August 9, 2024

Conditions

Healthy

Interventions

BIOLOGICAL

MK-6194

Subcutaneous Administration

BIOLOGICAL

Placebo

Subcutaneous administration

Trial Locations (1)

Peking University Third Hospital (Site 0001), Beijing

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06821334 - A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014) | Biotech Hunter | Biotech Hunter